The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

Chronic Obstructive Pulmonary Disease, COPD Clinical Trial

Official title:
A 24-week, Double Blind, Randomized Study to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Parameters Indicative of Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease

Status Completed

Clinical Trial Summary

The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Chronic Obstructive Pulmonary Disease, COPD
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive

Clinical Trial Details

NCT number	NCT00108823
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 3
Start date	October 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03064113` - Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)	Phase 2
Completed	`NCT00496470` - Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.	Phase 4
Completed	`NCT02442206` - Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients	Phase 4
Completed	`NCT03095456` - Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD	Phase 3
Completed	`NCT02615795` - Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease	N/A
Completed	`NCT02449018` - A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251	Phase 2